Trials / Conditions / Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Refractory Diffuse Large B-cell Lymphoma (DLBCL)
6 registered clinical trials studyying Refractory Diffuse Large B-cell Lymphoma (DLBCL) — 2 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymph NCT07480850 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting NCT05836896 | Technische Universität Dresden | Phase 1 |
| Recruiting | DALY II USA/ MB-CART2019.1 for DLBCL NCT04792489 | Miltenyi Biomedicine GmbH | Phase 2 |
| Active Not Recruiting | Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous NCT02570542 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgk NCT02348216 | Kite, A Gilead Company | Phase 1 / Phase 2 |
| Completed | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymp NCT01742988 | Curis, Inc. | Phase 1 |